Pivotal DREAMM-2 study: Single-agent belantamab mafodotin (belamaf; GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) refractory to proteasome inhibitors and immunomodulatory agents, and refractory and/or intolerant to anti-CD38 monoclonal antibodies (mAbs), including subgroups with renal impairment (RI) and high-risk (HR) cytogenetics Meeting Abstract
| Authors: | Lonial, S.; Lee, H. C.; Badros, A.; Trudel, S.; Nooka, A. K.; Chari, A.; Abdallah, A. O.; Callander, N. S.; Sborov, D. W.; Suvannasankha, A.; Weisel, K.; Voorhees, P. M.; Hultcrantz, M.; Libby, E. N.; Richardson, P. G.; Otero, P. R.; Besemer, B.; Facon, T.; Hoos, A.; Zhi, E.; Baron, J.; Piontek, T.; Jewell, R. C.; Lewis, E.; Opalinska, J.; Gupta, I.; Cohen, A. D. |
| Abstract Title: | Pivotal DREAMM-2 study: Single-agent belantamab mafodotin (belamaf; GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) refractory to proteasome inhibitors and immunomodulatory agents, and refractory and/or intolerant to anti-CD38 monoclonal antibodies (mAbs), including subgroups with renal impairment (RI) and high-risk (HR) cytogenetics |
| Meeting Title: | 8th Annual Meeting of the Society of Hematologic Oncology (SOHO) |
| Keywords: | survival; overall survival; response; progression-free; overall response rate; antibody-drug conjugate; duration of; belantamab mafodotin; belamaf; relapsed/refractory multiple myeloma |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 20 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2020 Sep 9-12 |
| Meeting Location: | Houston, TX |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2020-09-01 |
| Start Page: | S301 |
| End Page: | S302 |
| Language: | English |
| ACCESSION: | WOS:000564055100323 |
| PROVIDER: | wos |
| DOI: | 10.1016/S2152-2650(20)30943-5 |
| Notes: | Meeting Abstract: MM-219 -- Due to COVID-19 pandemic, the conference was held virtually -- Source: Wos |
